Day: May 12, 2022

First Quarter 2022 Net Income of $466,000 ($0.14 per diluted share) v. $1,827,000 ($0.52 per diluted share) in Prior Period. Prior Period Includes $1,618,000 ($0.46 per diluted share) of PPP Loan Forgiveness. Exclusive of PPP Loan Forgiveness, Prior Period Net Income was $209,000 ($0.06 per diluted share) First Quarter EBITDA, as adjusted of $546,000 ($0.16 per diluted share) v. $1,903,000 ($0.54 per diluted share) in Prior Year Period. Exclusive of PPP Loan Forgiveness, Prior Period EBITDA, as adjusted was $285,000 ($0.08 per diluted share) Exclusive of Costs Relating to the Panel Products Acquisition, First Quarter 2022 Net Income was $564,000 ($0.16 per diluted share) and EBITDA, as adjusted was $644,000 ($0.19 per diluted share) HAUPPAUGE, N.Y., May 12, 2022 (GLOBE NEWSWIRE) — Orbit International Corp. (OTC PINK:ORBT) today...

TORONTO, May 12, 2022 (GLOBE NEWSWIRE) — Victoria Gold Corp. (TSX-VGCX) (“Victoria” or the “Company”) is pleased to announce its first quarter 2022 summary financial and operating results. The Company uses certain non-IFRS performance measures throughout this news release. Please refer to the “Non-IFRS Performance Measures” section of this news release for more information. All currency figures are Canadian $ unless stated otherwise. This release should be read in conjunction with the Company’s Financial Statements and Management’s Discussion and Analysis (“MD&A”) for the three months ended March 31, 2022 and 2021, available on the Company’s website or on SEDAR.First Quarter 2022 Highlights Gold produced 24,358 ouncesAverage gold price realized US$ 1,838Revenue US$ 46,950,612Gross Profit US$ 20,766,149Net...

FYARRO net product sales of $2.3 million in partial first quarter Dosing of patients initiated in PRECISION 1, a Phase 2 tumor-agnostic registration-directed trial evaluating nab-sirolimus in TSC1 or TSC2 altered solid tumors Conference call to be held today at 8:30 am EDTLOS ANGELES, May 12, 2022 (GLOBE NEWSWIRE) — Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced financial results for the first quarter of 2022 and provided a corporate update. “We are very pleased and encouraged by the strong demand for FYARRO since its February 22nd launch despite the ultra-rare nature of advanced malignant PEComa,” commented Neil Desai, Ph.D., Founder, President and Chief Executive...

CHICAGO, May 12, 2022 (GLOBE NEWSWIRE) — Fast Radius, Inc. (“Fast Radius”) (Nasdaq: FSRD), a cloud manufacturing and digital supply chain company, reported financial results for the first quarter ended March 31, 2022. First Quarter 2022 Financial SummaryRevenue increased 65% to $6.3 million in 2022 compared to $3.8 million in first quarter 2021; Total Bookings were $7 million in 2022, an increase of 36% compared to first quarter 2021; Net loss was $44.6 million in 2022, or $0.73 per diluted share, compared to a net loss of $12.8 million, or $0.33 per diluted share, in first quarter 2021; and Adjusted EBITDA loss was $21.2 million in 2022 compared to a loss of $8.2 million in first quarter 2021.Management Commentary “In the first quarter, we grew revenue by 65% compared to the year ago period, driven by increased demand from...

LianBio’s partner, Bristol Myers Squibb, has received U.S. FDA approval of mavacamten for the treatment of patients with obstructive hypertrophic cardiomyopathy (oHCM)Registrational Phase 3 EXPLORER-CN clinical trial of mavacamten in Chinese patients with symptomatic oHCM ongoingLianBio’s partner, Tarsus, announced positive topline data from the Phase 3 Saturn-2 clinical trial of TP-03 in patients with Demodex blepharitisLianBio’s partner, ReViral, entered into definitive agreement to be acquired by PfizerThree additional pipeline programs expected to enter into registrational Phase 3 clinical trials in China by year-end 2022Cash balance of $389.1 million at the end of first quarter 2022 with runway through mid- 2024SHANGHAI, China and PRINCETON, N.J., May 12, 2022 (GLOBE NEWSWIRE) — LianBio (Nasdaq: LIAN), a biotechnology...

Announces Submission of Investigational New Drug (IND) Application for Decoy20 On Track to Initiate Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors in Second Half of 2022 NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) — Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), today announces financial results for the first quarter ended March 31, 2022 and provides a corporate update. “We are delighted to report the submission of our Investigational New Drug (IND) application for systemically administered Decoy20. The timing of this submission keeps us on track to initiate our first in human clinical trial this year and we look forward to working with the FDA as we move through the IND submission process,” said Jeffrey Meckler, Chief Executive Officer of Indaptus. “Decoy20, with its ability...

Total Revenue Increases 11% Period-over-Period and PBRT Revenue Increases 33% SAN FRANCISCO, CA, May 12, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — American Shared Hospital Services (NYSE American: AMS) (the “Company”), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced financial results for the first quarter ending March 31, 2022. First Quarter 2022 Financial HighlightsTotal revenue in the first quarter was $4,847,000, an increase of 11.1% from the comparable period in 2021. Total proton therapy revenue and fractions increased 33.2% and 32.3%, respectively, period-over-period. Gamma Knife revenue and volumes for same centers in operation increased 7.2% and 1.9%, respectively, when compared to Gamma Knife volumes...

Key financial highlightsRevenue growth of 32.6%, reaching $51.9 M for Q3-FY2022 from $39.2 M for Q3-FY2021, driven by organic revenue growth of $6.0 M, or 15.3%, and acquisition growth of $6.7 M, or 17.3%; Adjusted EBITDA1 reached $5.3 M, or 10.3% of revenues, for Q3-FY2022, compared to $4.5 M, or 11.5% of revenues, for Q3-FY2021; and Adjusted net earnings1 amounted to $3.4 M or $0.038 per share for Q3-FY2022 compared to adjusted net earnings of $2.2 M or $0.027 per share for Q3-FY2021.Subsequent event highlightOn April 4, 2022, the Corporation announced that it had recently renewed its contract with its largest operation and maintenance customer, the City of Gulfport, Mississippi. The expanded four-year contract, valued at $55.5 M, brought the Corporation’s O&M backlog to $131.0 M on April 4, 2022. On April 12, 2022, the Corporation...

Cash position bolstered through debt financing to support operations into the fourth quarter of 2023 NEEDHAM, Mass., May 12, 2022 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update. “2022 is off to a great start as we continue to advance our late-stage pipeline of novel oncolytic viral immunotherapies for cancer,” said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel. “Today, we are well positioned for major catalysts over the next 12 months, namely multiple clinical data readouts across our product candidates and advancement of our...

Phase 1 clinical trial of INB-100 in leukemia patients and INB-200 in newly diagnosed glioblastoma multiforme (GBM) patients continue to generate encouraging data. INB-100 patient update at European Group for Blood and Marrow Transplantation (EBMT) 48th Annual Meeting demonstrated that all three treated patients remain in morphologic complete response (CR) with two patients approaching relapse free survival of 21 to 23 months as of March 2022. INB-200 continues to enroll and treat patients in cohort 2 with one patient having received all three anticipated repeat doses of INB-200, the first-ever repeat dosing of a genetically modified gamma-delta T cell therapy. A clinical update is expected at the American Society of Clinical Oncology (ASCO) Annual Meeting in June 2022 (Abstract # 2044). In May 2022, IN8bio unveiled a new program focused...